Kura Oncology, Inc. $KURA Shares Sold by Armistice Capital LLC

Armistice Capital LLC trimmed its holdings in Kura Oncology, Inc. (NASDAQ:KURA) by 5.7% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 6,200,000 shares of the company’s stock after selling 372,000 shares during the quarter. Kura Oncology accounts for approximately 0.6% of Armistice Capital LLC’s investment portfolio, making the stock its 22nd biggest holding. Armistice Capital LLC owned 7.14% of Kura Oncology worth $35,774,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the stock. BVF Inc. IL increased its stake in shares of Kura Oncology by 202.0% in the 1st quarter. BVF Inc. IL now owns 7,754,129 shares of the company’s stock valued at $51,177,000 after purchasing an additional 5,186,660 shares in the last quarter. Qube Research & Technologies Ltd lifted its position in Kura Oncology by 63.0% in the second quarter. Qube Research & Technologies Ltd now owns 1,911,886 shares of the company’s stock valued at $11,032,000 after buying an additional 738,761 shares during the last quarter. AQR Capital Management LLC increased its holdings in Kura Oncology by 407.8% in the 1st quarter. AQR Capital Management LLC now owns 760,332 shares of the company’s stock valued at $5,018,000 after purchasing an additional 610,604 shares during the last quarter. Jacobs Levy Equity Management Inc. boosted its holdings in Kura Oncology by 57.9% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 1,544,113 shares of the company’s stock valued at $10,191,000 after acquiring an additional 566,193 shares during the period. Finally, Acadian Asset Management LLC lifted its holdings in Kura Oncology by 163.6% during the 2nd quarter. Acadian Asset Management LLC now owns 870,903 shares of the company’s stock worth $5,022,000 after buying an additional 540,482 shares in the last quarter.

Kura Oncology Trading Down 2.6%

NASDAQ:KURA opened at $10.46 on Friday. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.12 and a quick ratio of 5.12. Kura Oncology, Inc. has a 12 month low of $5.41 and a 12 month high of $12.49. The business’s 50-day moving average is $10.58 and its two-hundred day moving average is $8.17. The firm has a market capitalization of $910.23 million, a PE ratio of -4.22 and a beta of 0.21.

Kura Oncology (NASDAQ:KURA) last posted its earnings results on Tuesday, November 4th. The company reported ($0.85) EPS for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.28). The firm had revenue of $20.75 million for the quarter, compared to analyst estimates of $17.48 million. Kura Oncology had a negative return on equity of 65.42% and a negative net margin of 208.48%. Research analysts predict that Kura Oncology, Inc. will post -2.44 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on KURA. Guggenheim started coverage on shares of Kura Oncology in a report on Thursday, September 4th. They issued a “neutral” rating on the stock. Citigroup reiterated a “market outperform” rating on shares of Kura Oncology in a research note on Friday, December 5th. Wall Street Zen raised shares of Kura Oncology from a “sell” rating to a “hold” rating in a report on Sunday, August 17th. UBS Group increased their target price on shares of Kura Oncology from $14.00 to $16.00 and gave the company a “buy” rating in a report on Friday, November 14th. Finally, JMP Securities restated a “market outperform” rating and set a $24.00 target price on shares of Kura Oncology in a report on Monday, October 20th. Eight investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Kura Oncology presently has a consensus rating of “Moderate Buy” and an average target price of $26.57.

Insider Activity

In other Kura Oncology news, insider Teresa Brophy Bair sold 8,805 shares of the business’s stock in a transaction on Monday, September 29th. The shares were sold at an average price of $8.94, for a total transaction of $78,716.70. Following the completion of the sale, the insider owned 148,043 shares in the company, valued at $1,323,504.42. The trade was a 5.61% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Troy Edward Wilson sold 36,615 shares of the firm’s stock in a transaction dated Monday, September 29th. The stock was sold at an average price of $8.94, for a total transaction of $327,338.10. Following the completion of the transaction, the chief executive officer directly owned 246,853 shares in the company, valued at $2,206,865.82. This represents a 12.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 122,675 shares of company stock worth $1,196,657 over the last ninety days. Insiders own 6.40% of the company’s stock.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.